Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 sales and earnings announced for quarter ended June 28, 2026.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 sales and earnings announced for quarter ended June 28, 2026
- Exhibit 99.1 contains the financial results and management commentary
- Results provide an updated view of Johnson & Johnson’s operating performance and outlook
Item EX-99.1 · Exhibit EX-99.1
- Q2 sales $25.3B, up 6.6%; adjusted EPS $2.90, up 4.7%, signaling solid operating momentum
- Innovative Medicine led growth at 6.8% operationally, while MedTech increased 3.6%
- Full-year reported sales outlook raised to $101.1B midpoint, implying 7.3% growth and first annual revenue above $100B
- Adjusted EPS guidance increased $0.13 to $11.68 midpoint, with adjusted operational EPS raised $0.18 to $11.58
- Pipeline catalysts include TREMFYA, CAPLYTA, RYBREVANT FASPRO, TECVAYLI, and planned Firefly Bio acquisition exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.